GleamWall
中文EN

VRDN Viridian Therapeutics, Inc.\DE

Pharmaceutical Preparations · Nasdaq · SEC CIK 1590750 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-62.8%
TTM net income YoY-50.2%
TTM EPS YoY—
Revenue 3-yr CAGR323.2%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,781.4%
Net margin-1,724.1%
FCF margin-1,305.4%
EBITDA margin-1,778.7%

Returns

ROE-83.7%
ROA-56.5%
ROIC (approx.)-97.2%
Asset turnover0.03x

Leverage & solvency

Liabilities / assets43.5%
Debt / equity0.00x
Current ratio14.46x
Interest coverage-19.27x

Cash quality & payout

Operating cash flow / net income0.75x
Accruals ratio-14.0%
Payout ratio—
Capex / revenue7.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$25.75M$284,000$141,000$132,000$70.57M$75,000$72,000$72,000
Cost of revenue$1.53M———$0———
Gross profit$24.23M———$70.57M———
R&D expense$70.09M$71.58M$77.63M$89.21M$86.26M$86.63M$76.83M$71.96M
SG&A expense$57.61M$54.98M$38.68M$33.67M$24.32M$20.22M$17.10M$15.58M
Operating income-$103.48M-$126.27M-$116.17M-$122.75M-$40.01M-$106.77M-$93.87M-$87.47M
Interest expense$9.27M$8.31M$3.46M$3.28M$560,000$514,000$550,000$517,000
Net income-$101.21M-$127.12M-$104.90M-$120.36M-$34.60M-$100.73M-$86.91M-$79.72M
EBITDA-$103.13M-$126.15M-$116.05M-$122.63M-$39.90M-$106.65M-$93.75M-$87.35M
EPS (diluted)————————
Weighted avg. shares (diluted)————81.78M81.59M81.34M—
Balance sheet
Cash & equivalents$172.86M$164.99M$176.35M$212.38M$169.65M$117.32M$116.22M$99.59M
Short-term investments$782.35M$816.54M$585.84M$662.27M$321.25M$446.03M$520.42M$617.99M
Receivables$29.78M——$0————
Inventory$85,000——$0————
Current assets$1.01B$1.08B$784.74M$894.23M$571.91M$578.75M$657.24M$738.46M
PP&E, net$2.97M$2.77M$1.13M$1.23M$1.12M$1.09M$1.16M$1.24M
Intangibles$9.79M$10.00M—$0————
Total assets$1.03B$1.10B$789.02M$899.42M$577.14M$582.32M$660.98M$742.40M
Current liabilities$70.05M$63.79M$51.80M$70.70M$50.70M$52.59M$33.73M$47.87M
Short-term debt—————$8.44M—$0
Long-term debt————$20.89M$12.35M$20.68M$20.58M
Total debt————$20.89M$20.79M$20.68M$20.58M
Total liabilities$447.97M$435.14M$153.01M$177.25M$74.17M$67.16M$56.51M$70.76M
Shareholders' equity$580.70M$662.10M$636.01M$722.17M$502.97M$515.17M$604.47M$671.64M
Net debt————-$148.76M-$96.54M-$95.53M-$79.01M
Shares outstanding113.53M113.24M102.46M101.83M82.23M81.65M81.59M80.99M
Cash flow statement
Operating cash flow-$92.77M-$105.32M-$119.65M-$23.75M-$84.61M-$75.37M-$92.65M-$73.33M
Capital expenditure$370,000$1.31M$23,000$240,000$127,000$42,000$86,000$114,000
Free cash flow-$93.14M-$106.63M-$119.68M-$23.99M-$84.74M-$75.42M-$92.74M-$73.45M
Investing cash flow$24.34M-$231.16M$77.26M-$339.42M$126.08M$75.72M$100.06M-$62.91M
Financing cash flow$77.61M$325.12M$6.36M$405.91M$10.86M$764,000$9.21M$35.52M
Depreciation & amortization$343,000$117,000$121,000$120,000$110,000$113,000$117,000$123,000
Stock-based compensation$17.23M$16.98M$13.39M$11.99M$11.25M$10.84M$10.22M$8.97M

Free plan shows the latest 8 periods; Pro shows all 54 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.